Results for: S2000-025測試 💫 S2000-025學習筆記 🌵 S2000-025最新題庫資源 👱 透過➡ www.newdumpspdf.com ️⬅️搜索➡ S2000-025 ️⬅️免費下載考試資料S2000-025考題資源

Gum disease linked to cognitive decline in AD

December 7, 2016

…he community (Raybould et al. PLoS One 2016;11:e0151081, free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC4786266/pdf/pone.0151081.pdfAbstract). Subjects were assessed at baseline and at 6 months. The primary outcome measure was change from baseline in ADAS-cog. Blood samples were obtained for C-reactive protein (CRP) inflammatory cytokines (tumour necrosis factor-alpha, interleukin-10), and antibodies to Porphyromonas gingivalis, a Gram-neg…

Iatrogenic Alzheimer’s – is AD transmissible?

November 9, 2016

…on-to-person contact. (For a podcast of researcher Dr. John Collinge go to www.nature.com/nature/podcast/index-2016-03-17.html). Then earlier this year, a second study found similar findings (Frontzek et al. Swiss Med Weekly; free full text at www.smw.ch/content/smw-2016-14287/). The autopsy study examined seven subjects who died of iatrogenic CJD after dural grafting. Over 200 CJD deaths have been reported following dural grafts obtained from cad…

Phase III results for siponimod in SPMS

September 28, 2016

…o in the proportion of patients with confirmed disability progression on a composite endpoint (EDSS, Timed 25-Foot Walk [T25FW], 9-Hole Peg Test [9HPT]); improvement was seen on the 9HPT. For EXPAND, a total of 1651 subjects were randomized to placebo or a starting dose of siponimod 0.25 mg x 6 days, increased to 2.0 mg/day. The primary outcome was time to three-month confirmed disability progression (CDP). Siponimod was associated with a mean 21%…

ECTRIMS DAILY REPORT – FRIDAY EDITION

September 16, 2016

…During the 58-month observation period there was >80% adherence. The most common reason for discontinuation was adverse effects; the most common AE associated with discontinuation was low lymphocyte counts. A separate study examined the effect of fingolimod on cognition in 105 patients treated for up to 3 years (Ozakbas et al. ECTRIMS 2016; abstract P619). Fingolimod-treated patients showed improvements from baseline in the Symbol Digit Modalitie…

EMD Serono’s LAUNCH program – A model for academia/industry partnerships

September 7, 2016

….” EMD Serono has continued to support LAUNCH in large part because of the commitment shown by faculty members, and the feedback the company has received from participants. “To run the practice OSCEs requires a lot from our faculty – it takes effort and stamina for them to perform 528 exams in one day,” Murphy said. “But they continue to come back – and some have been with the program since its inception. “The residents have told us how valuable t…